Table 1 Relationship between expression of miR‑100 and clinical characteristics of MCL cases
From: miR-100 inhibits cell proliferation in mantle cell lymphoma by targeting mTOR
Clinical features | n | High miR-100 | Low miR-100 | χ2 | p value |
|---|---|---|---|---|---|
Age (years) | Â | Â | Â | 0.9 | 0.3428 |
 ≤ 58 | 8 | 5 | 3 |  |  |
 >58 | 10 | 4 | 6 |  |  |
Sex | Â | Â | Â | 0.2769 | 0.5987 |
 Male | 13 | 6 | 7 |  |  |
 Female | 5 | 3 | 2 |  |  |
B symptoms | Â | Â | Â | 2.25 | 0.1336 |
 Present | 2 | 0 | 2 |  |  |
 Absent | 16 | 9 | 7 |  |  |
LDH (U/L) | Â | Â | Â | 6.923 | 0.0085 |
 <300 | 13 | 9 | 4 |  |  |
 ≥ 300 | 5 | 0 | 5 |  |  |
Clinical stage | Â | Â | Â | 3.6 | 0.0578 |
 I–II | 3 | 3 | 0 |  |  |
 III–IV | 15 | 6 | 9 |  |  |
IPI score | Â | Â | Â | 5.844 | 0.0156 |
 <3 | 11 | 8 | 3 |  |  |
 ≥ 3 | 7 | 1 | 6 |  |  |
Involve bone marrow | Â | Â | Â | 0.2338 | 0.6287 |
 Present | 11 | 5 | 6 |  |  |
 Absent | 7 | 4 | 3 |  |  |